Reference | Age | Allergen level | Non-asthmatics | Asthmatics | OR | Population attributable risk | Definition of asthma | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. | Exposed | No. | Exposed | |||||||||||||||||
Sporik et al 21 | 1–15 (asthmatics) | >10 μg/g Der p1 | 44 | 70% | 82 | 76% | 1.31-150 | 16% | Asthma patients for hospital treatment | |||||||||||
10–12 (non-asthmatics) | ||||||||||||||||||||
Callet al 22 | 3–15 | ⩾10 μg/g HDM grp 1 | 22 | 45% | 35 | 26% | 0.41-150 | −39% | Asthma patients for hospital treatment | |||||||||||
Verhoeff et al 23 | 6–12 | >2 μg/gDer p1 | 257 | 89% | 259 | 83% | 0.61-150 | −55% | Chronic respiratory symptoms | |||||||||||
>10 μg/gDer p1 | 257 | 57% | 259 | 54% | 0.91-150 | −6% | ||||||||||||||
Platts Mills et al 24 | 12–14 | >2 μg/g HDM grp 1 | 47 | 6% | 50 | 4% | 1.41-150 | 1% | Chronic respiratory symptoms | |||||||||||
>10 μg/g HDM grp 1 | 47 | 0% | 50 | 0% | – | – | Wheezing | |||||||||||||
Marks et al 25 | 8–10 | ⩾10 μg/gDer p1 | 35 | 97% | 39 | 100% | ∼1.11-150 | 9% | Wheezing or nocturnal cough; Wheezing, whistling or asthma | |||||||||||
Wickenset al 26 | 7–9 | >10 μg/gDer p 1 (living room) | 241 | 79% | 233 | 82% | 1.2 | 16% | Wheezing or nocturnal cough; Wheezing, whistling or asthma | |||||||||||
>10 μg/g Der p 1 (bedroom) | 241 | 83% | 233 | 85% | 1.2 | 20% | ||||||||||||||
>10 μg/g Der p 1 (bedding) | 241 | 95% | 233 | 90% | 0.5 | −90% |
↵1-150 Calculated.